FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series C / Biotech startups that raised Series C in Massachusetts, United States

Biotech startups that raised Series C in Massachusetts, United States

Updated 16 Nov 2026

Reset
Biotech startups that raised Series C in Massachusetts, United States
One-time CSV
  • 70 funded companies, 67 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-c~massachusetts-united-states.csv70 rows × 18 columns
CompanyCityLast roundAmountDate
Delix TherapeuticsBostonSeries C$100.0M2026-11-09
Ratio TherapeuticsBostonSeries C$70.0M2026-07-31
Triveni BioWatertownSeries C$65.0M2026-06-17
CereVascCharlestownSeries C$85.0M2026-06-04
CerevanceBostonSeries C$20.0M2026-05-12
Terrestrial BioCambridgeSeries C$50.0M2026-03-26
Cognito TherapeuticsCambridgeSeries C$105.0M2026-03-05
ElektrofiBostonSeries C$112.2M2024-08-22

8 rows of the CSV in 5 of its 18 columns.

70
Startups
$10.5B
Total raised
10
Funded in the last 12 months
$632.0M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

10 of 70
10 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Delix Therapeutics Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. Biotech Boston Series C $100.0M 2026-11-09 $244.1M Gaingels, RA Capital Management, Dolby Family Ventures +2 11 to 50 2019
Ratio Therapeutics Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. Biotech Boston Series C $70.0M 2026-07-31 $160.0M Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments 11 to 50 2021
Triveni Bio Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. Biotech Watertown Series C $65.0M 2026-06-17 $272.0M Polaris Partners, OrbiMed, Alexandria Venture Investments +2 11 to 50 2019
CereVasc CereVasc develops a minimally invasive treatment for communicating hydrocephalus. Biotech Charlestown Series C $85.0M 2026-06-04 $199.0M Perceptive Advisors, Bain Capital Life Sciences, ATON Partners 11 to 50 2014
Cerevance Cerevance develops novel therapeutics for neurological diseases. Biotech Boston Series C $20.0M 2026-05-12 $209.5M Google Ventures, Casdin Capital, Foresite Capital +1 51 to 100 2016
Terrestrial Bio Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. Biotech Cambridge Series C $50.0M 2026-03-26 $180.9M RA Capital Management, National Institutes of Health, The Engine 11 to 50 2012
Cognito Therapeutics Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. Biotech Cambridge Series C $105.0M 2026-03-05 $321.8M Morningside, FoundersX Ventures, IAG Capital Partners +1 11 to 50 2016
Sionna Therapeutics Sionna Therapeutics develops small molecule therapies for treating cystic fibrosis. Biotech Natick Series C $182.0M 2024-03-06 $292.0M RA Capital Management, OrbiMed, T. Rowe Price +2 11 to 50 2018
Accent Therapeutics Accent Therapeutics is a biopharmaceutical company. Biotech Lexington Series C $75.0M 2024-01-23 $178.0M Google Ventures, Mirae Asset Venture Investment, Bristol-Myers Squibb +2 11 to 50 2017
ConcertAI Unicorn ConcertAI sells AI-powered SaaS data tools for medical research in oncology. Artificial intelligence Cambridge Series C $150.0M 2022-03-29 $300.0M Maverick Ventures, Sixth Street, Declaration Partners +2 1,001 to 5,000 2018

Table 1. Biotech startups that raised Series C in Massachusetts, United States: the 10 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 70.

Largest rounds

Last 12 months
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 Cognito Therapeutics Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. Biotech Cambridge Series C $105.0M 2026-03-05 $321.8M Morningside, FoundersX Ventures, IAG Capital Partners +1 11 to 50 2016
2 Delix Therapeutics Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. Biotech Boston Series C $100.0M 2026-11-09 $244.1M Gaingels, RA Capital Management, Dolby Family Ventures +2 11 to 50 2019
3 CereVasc CereVasc develops a minimally invasive treatment for communicating hydrocephalus. Biotech Charlestown Series C $85.0M 2026-06-04 $199.0M Perceptive Advisors, Bain Capital Life Sciences, ATON Partners 11 to 50 2014
4 Ratio Therapeutics Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. Biotech Boston Series C $70.0M 2026-07-31 $160.0M Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments 11 to 50 2021
5 Triveni Bio Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. Biotech Watertown Series C $65.0M 2026-06-17 $272.0M Polaris Partners, OrbiMed, Alexandria Venture Investments +2 11 to 50 2019
6 Terrestrial Bio Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. Biotech Cambridge Series C $50.0M 2026-03-26 $180.9M RA Capital Management, National Institutes of Health, The Engine 11 to 50 2012
7 Cerevance Cerevance develops novel therapeutics for neurological diseases. Biotech Boston Series C $20.0M 2026-05-12 $209.5M Google Ventures, Casdin Capital, Foresite Capital +1 51 to 100 2016

Table 2. Biotech startups that raised Series C in Massachusetts, United States: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 RA Capital Management Startup incubator Boston, United States 4 6% 2 Delix Therapeutics, Terrestrial Bio
2 OrbiMed Private equity firm New York, United States 3 4% 1 Triveni Bio
3 Bristol-Myers Squibb Venture capital firm New York, United States 2 3% 1 Ratio Therapeutics
4 Invus Private equity firm New York, United States 2 3% 1 Triveni Bio
5 Polaris Partners Private equity firm Boston, United States 2 3% 1 Triveni Bio
6 Google Ventures Corporate venture arm San Francisco, United States 2 3% 1 Cerevance
7 Gaingels Syndicate Burlington, United States 1 1% 1 Delix Therapeutics
8 Casa Verde Capital Venture capital firm Los Angeles, United States 1 1% 1 Delix Therapeutics
9 Artis Ventures Venture capital firm San Francisco, United States 1 1% 1 Delix Therapeutics
10 Dolby Family Ventures Venture capital firm San Francisco, United States 1 1% 1 Delix Therapeutics
11 The Pags Group Family office Boston, United States 1 1% 1 Ratio Therapeutics
12 Schusterman Family Investments Family office New York, United States 1 1% 1 Ratio Therapeutics
13 Cormorant Asset Management Hedge fund Boston, United States 1 1% 1 Triveni Bio
14 Alexandria Venture Investments Venture capital firm Pasadena, United States 1 1% 1 Triveni Bio
15 ATON Partners Venture capital firm Boston, United States 1 1% 1 CereVasc

Table 3. Biotech startups that raised Series C in Massachusetts, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 65 93% $9.3B
Software 4 6% $1.2B
Artificial intelligence 3 4% $1.1B
Hardware 2 3% $363.5M

Table 4. Biotech startups that raised Series C in Massachusetts, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series C 70 100% $48.0M

Table 5. Biotech startups that raised Series C in Massachusetts, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Cambridge 23 33%
Boston 14 20%
Waltham 6 9%
Woburn 5 7%
Medford 3 4%
Charlestown 2 3%
Lexington 2 3%
Mansfield 2 3%
Burlington 1 1%
Watertown 1 1%
Natick 1 1%
Somerville 1 1%

Table 6. Biotech startups that raised Series C in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 2 20% $115.0M
July 2026 2 20% $107.0M
June 2026 3 30% $235.0M
May 2026 1 10% $20.0M
March 2026 2 20% $155.0M

Table 7. Biotech startups that raised Series C in Massachusetts, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 10 14% $632.0M
2025 8 11% $511.7M
2024 6 9% $662.2M
2023 1 1% $86.5M
2022 8 11% $736.0M
2021 6 9% $297.0M

Table 8. Biotech startups that raised Series C in Massachusetts, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2020 to 2022 4 6%
2015 to 2019 30 43%
2010 to 2014 12 17%
Before 2010 24 34%

Table 9. Biotech startups that raised Series C in Massachusetts, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 4 6%
11 to 50 32 46%
51 to 100 20 29%
101 to 250 9 13%
251 to 500 2 3%
501 to 1,000 2 3%
1,001 to 5,000 1 1%

Table 10. Biotech startups that raised Series C in Massachusetts, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Massachusetts, United States whose last round is Series C are on the list?
70, in the file dated 16 November 2026. 10 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 70 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series C in Massachusetts, United States: 70 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in Massachusetts

Other sectors that raised Series C in Massachusetts

Cite: FundingWatcher, 70 biotech companies in Massachusetts, United States whose most recent round is Series C, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-c/massachusetts-united-states/